Citadel Securities LLC recently announced the acquisition of new stake in Ensysce Biosciences Inc (NASDAQ:ENSC). This fresh investment now brings its stake to 0.61% valued currently at $20260.0. In addition, Geode Capital Management LLC raised its holdings by 16430.0 to 16430.0 shares.
Currently, there are 3.15M common shares owned by the public and among those 2.81M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 199,587 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Ensysce Biosciences Inc are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Series Total Market Inde. Vanguard Extended Market Index Fu owns 18175.0 shares of the company’s stock, all valued at over $19266.0. Fidelity Series Total Market Inde now owns shares totaling to 0.00% of the shares outstanding.
However, the script later moved the day high at 1.9000, up 21.93%. The company’s stock has a 5-day price change of 23.01% and 11.20% over the past three months. ENSC shares are trading 31.13% year to date (YTD), with the 12-month market performance down to -82.90% lower. It has a 12-month low price of $0.76 and touched a high of $18.36 over the same period. ENSC has an average intraday trading volume of 196.43K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 20.67%, 34.11%, and -27.26% respectively.
Institutional ownership of Ensysce Biosciences Inc (NASDAQ: ENSC) shares accounts for 6.22% of the company’s 3.15M shares outstanding. Mutual fund holders own 1.10%, while other institutional holders and individual stakeholders account for 4.24% and — respectively.
It has a market capitalization of $4.38M and a beta (3y monthly) value of 0.87. The earnings-per-share (ttm) stands at -$7.76. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.08% over the week and 12.17% over the month.
Analysts forecast that Ensysce Biosciences Inc (ENSC) will achieve an EPS of -$0.87 for the current quarter, -$0.83 for the next quarter and -$3.34 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.93 while analysts give the company a high EPS estimate of -$0.81. Comparatively, EPS for the current quarter was -$18.24 a year ago. Earnings per share for the fiscal year are expected to increase by 58.69%, and 30.42% over the next financial year.
